footandmouth
diseas
viru
fmdv
highli
infecti
member
picornavirida
induc
acut
diseas
clovenhoof
speci
vaccineinduc
immun
protect
correl
presenc
high
level
neutral
antibodi
also
opsonis
antibodi
propos
import
mechan
immun
respons
contribut
viru
clearanc
macrophag
lead
product
typei
interferon
ifn
plasmacytoid
dendrit
cell
pdc
present
studi
demonstr
opsonis
antibodi
titr
mediat
enhanc
respons
pdc
similar
neutral
titr
antigen
relat
virus
serotyp
employ
howev
sera
crossreact
also
nonneutr
isol
multipl
serotyp
test
assay
uncomplex
viru
immun
complex
viru
stimul
pdc
via
tolllik
receptor
addit
find
potenti
import
strainspecif
differ
virul
andor
immunogen
pdc
activ
fmdv
strongli
differ
viral
isol
altogeth
result
indic
opsonis
antibodi
broader
reactiv
neutral
antibodi
may
contribut
antivir
respons
induc
antigen
distant
virus
footandmouth
diseas
viru
fmdv
highli
contagi
infecti
agent
induc
diseas
clovenhoof
anim
includ
cattl
swine
goat
sheep
due
signific
econom
impact
livestock
tight
diseas
control
requir
howev
high
mutat
rate
contribut
immun
escap
presenc
seven
serotyp
c
south
african
territori
contain
larg
varieti
isol
high
antigen
variabl
current
convent
vaccin
consist
inactiv
viru
provid
shortterm
serotyp
specif
protect
howev
vaccin
induc
protect
isol
within
one
serotyp
protect
relat
presenc
high
level
neutral
antibodi
serum
howev
anim
low
level
neutral
antibodi
also
protect
furthermor
nonneutr
concentr
monoclon
antibodi
mab
induc
protect
mice
thu
mechan
neutral
could
involv
protect
shown
opsonis
fmdv
enhanc
phagocytosi
monocyt
macrophag
vitro
recent
vivo
data
emphas
potenti
role
opsonis
antibodi
mous
model
protect
mediat
macrophagedepend
manner
studi
indic
immun
complex
viru
could
elimin
phagocytosi
macrophag
bear
fc
receptor
fcr
studi
also
indic
particip
dendrit
cell
dc
least
vitro
immun
complex
induc
activ
porcin
plasmacytoid
dc
pdc
result
product
interferon
ifn
possibl
involv
opsonis
antibodi
fmdv
immun
also
confirm
bovin
pdc
pdc
repres
porcin
peripher
blood
mononuclear
cell
pbmc
similar
function
characterist
human
murin
counterpart
character
produc
high
amount
antivir
typei
ifn
respons
wide
rang
pathogen
pdc
activ
mediat
sens
pathogenassoci
molecular
pattern
pamp
pattern
recognit
receptor
prr
express
prr
tolllik
receptor
tlr
ctype
lectin
receptor
pdc
contribut
innat
adapt
antivir
immun
antibodydepend
fmdv
entri
pdc
occur
via
receptor
link
pdc
adapt
immun
consid
possibl
import
opsonis
antibodi
pdc
protect
fmdv
main
aim
studi
character
relationship
neutral
opsonis
activ
polyclon
sera
immun
pig
although
neutral
opsonis
occur
similar
serum
dilut
antigen
relat
virus
employ
opsonis
also
occur
absenc
neutral
across
differ
serotyp
also
discov
differ
abil
variou
fmdv
isol
activ
pdc
pdc
enrich
monoclon
antibodi
follow
cell
surfac
marker
use
mab
mab
mab
mab
phenotyp
mab
use
hybridoma
mab
kindli
provid
dr
veterinari
univers
vienna
austria
mab
purchas
vmrd
pullman
wa
usa
unsort
sort
see
pbmc
cultur
dulbecco
modifi
eagl
minim
essenti
medium
dmem
plu
glutamax
gibco
life
technolog
basel
switzerland
supplement
life
technolog
co
babi
hamster
kidney
bhk
cell
grown
glasgow
minimum
essenti
medium
gmem
life
technolog
supplement
vv
fetal
bovin
serum
fb
south
america
origin
biowest
franc
viru
prepar
serum
neutral
test
cell
cultur
fbsfree
gmem
co
blood
collect
altern
total
specif
pathogenfre
spf
pig
month
old
kept
institut
pbmc
isol
citrat
blood
use
ficol
paqu
gl
amersham
pharmacia
biotech
ag
dubendorf
switzerland
densiti
gradient
pdc
enrich
pbmc
separ
use
magnet
sort
system
mac
deplet
ld
select
ls
column
miltenyi
biotech
gmbh
bergischgladbach
germani
pdc
enrich
either
use
posit
select
ld
column
first
deplet
cell
subsequ
posit
select
cell
altern
pbmc
isol
use
ficol
paqu
optiprep
wv
solut
oidixanol
water
sigmaaldrich
saint
loui
mo
usa
densiti
gradient
follow
deplet
cell
final
enrich
cell
puriti
sort
popul
verifi
flow
cytometri
detect
stain
mab
isotypespecif
rphycoerythrin
rpe
fluorescein
isothiocyan
fitc
conjug
southern
biotechnolog
associ
birmingham
al
usa
describ
pdc
popul
identifi
high
low
cell
flow
cytometri
isol
fmdv
propag
cell
previous
describ
viral
titr
determin
endpoint
titrat
cell
ukg
novil
bulgaria
vietnam
brazil
kindli
provid
dr
nigel
ferri
satya
parida
institut
anim
health
pirbright
uk
order
avoid
heparin
sulphat
adapt
viru
isol
passag
three
time
cell
mock
antigen
prepar
uninfect
cell
manner
fmdv
two
spf
pig
immun
intramuscularli
fulldos
monoval
fmdv
vaccin
consist
inactiv
typeo
manisa
antigen
merial
lyon
franc
anim
receiv
prime
inject
day
booster
day
day
blood
sampl
taken
serum
prepar
storag
serum
sampl
anim
litter
use
control
certain
experi
serum
complement
inactiv
heattreat
min
serial
dilut
heattreat
serum
incub
room
temperatur
rt
min
tcid
fmdv
isol
form
immun
complex
final
volum
ad
confluent
cell
grown
plate
day
neutral
titr
calcul
accord
kaerber
base
fmdvinduc
cytopathogen
effect
cpe
isol
pbmc
sort
cell
cellsml
stimul
serumfre
medium
fmdv
fmdvimmun
serum
mixtur
serum
mixtur
sera
use
either
untreat
heattreat
fmdvserum
mixtur
previous
form
min
control
cell
stimul
cpg
invitrogen
basel
switzerland
influenza
viru
strain
employ
test
specif
inhibitor
control
oligonucleotid
odn
sequenc
use
ctrlodn
purchas
eurofin
mwg
operon
ebersberg
germani
influenza
viru
grown
day
embryon
chicken
egg
titrat
previous
describ
pdc
activ
influenza
viru
employ
multipl
infect
moi
tcid
cell
supernat
enrich
pdc
harvest
h
detect
specif
elisa
describ
data
collect
use
versamax
photomet
softmax
pro
softwar
signific
differ
determin
sigmaplot
use
sum
rank
test
p
previous
document
pdc
activ
fmdv
occur
presenc
specif
antibodi
howev
experi
perform
pdc
enrich
fold
pbmc
use
posit
select
magnet
cell
sort
figur
therefor
effici
purif
method
evalu
studi
pdc
nont
cell
found
within
high
pbmc
base
pbmc
first
deplet
monocyt
subsequ
enrich
use
result
frequenc
pdc
fold
enrich
depend
experi
third
protocol
employ
deplet
subsequ
enrich
pbmc
result
pdc
popul
figur
type
cpg
oligonucleotid
like
cpg
odn
potent
activ
secret
porcin
pdc
employ
posit
control
cpg
induc
hundr
unit
unpurifi
pbmc
magnet
cell
sort
product
increas
fold
littl
differ
differ
purif
protocol
figur
contrast
pdc
stimul
fmdv
ukg
report
previous
stimul
pbmc
pbmc
term
product
observ
protocol
employ
either
subsequ
pbmc
subsequ
pbmc
permit
induct
stimul
fmdv
ukg
figur
import
note
respons
rang
time
lower
seen
cpg
stimul
level
significantli
higher
pbmc
compar
pbmc
number
cell
obtain
upon
enrich
higher
latter
protocol
deplet
enrich
method
employ
follow
experi
test
capac
differ
fmdv
isol
activ
pdc
found
remark
differ
exemplifi
three
differ
fmdv
isol
employ
moi
tcid
cell
figur
lowest
moi
detect
stimul
bulgaria
moi
tcid
cell
turkey
induc
weak
respons
bulgaria
rel
strong
respons
respons
increas
viru
dose
doubl
ukg
remain
poor
induc
figur
consid
result
test
fmdv
isol
abil
activ
pdc
moi
tcid
cell
figur
result
confirm
abil
fmdv
activ
pdc
vari
consider
even
within
one
serotyp
rel
strong
induc
bulgaria
turkey
weak
induc
vietnam
ukg
ineffici
induc
novil
brazil
turkey
previou
studi
use
purifi
subtypespecif
antibodi
high
concentr
serotypespecif
immun
serum
form
fmdv
immun
complex
interest
determin
relationship
serum
concentr
enhanc
opsonis
fmdv
ukg
serum
neutral
titr
nt
log
dilut
log
induc
pdc
activ
figur
fact
high
serum
concentr
show
suppress
effect
pdc
stimul
fmdv
independ
immun
statu
donor
anim
data
shown
therefor
omit
remain
experi
increas
serum
dilut
immun
complex
enhanc
pdcproduc
even
moi
low
tcid
cell
immun
complex
activ
pdc
figur
approach
appli
bulgaria
high
induc
fmdv
isol
figur
serum
employ
show
nt
log
viru
bulgaria
moi
tcid
ml
immun
serum
enhanc
pdcderiv
respons
expect
concentrationdepend
manner
maximum
level
serum
dilut
log
gradual
loss
enhanc
activ
serum
dilut
figur
contrast
bulgaria
use
moi
tcid
cell
serum
concentrationdepend
relationship
observ
figur
particular
highest
viru
dose
clear
enhanc
respons
observ
conclud
low
moi
employ
measur
antibodydepend
enhanc
respons
pdc
high
fmdv
isol
use
result
obtain
variou
serum
dilut
variou
fmdv
isol
indic
serum
factor
specif
immunoglobulin
ig
influenc
pdc
activ
reason
naiv
serum
titrat
parallel
immun
serum
possibl
impact
complement
test
heattreat
sera
form
immun
complex
figur
show
repres
experi
immun
serum
enhanc
respons
induc
fmdv
ukg
rel
naiv
serum
nevertheless
enhanc
clear
serum
dilut
log
figur
heattreat
sera
immun
complex
enhanc
pdcderiv
clearli
visibl
statist
differ
serum
dilut
log
conclud
complement
requir
enhanc
immuneserum
heatlabil
serum
factor
could
even
suppress
effect
consid
experi
perform
heattreat
serum
previou
work
demonstr
fmdv
immun
complexmedi
pdc
activ
requir
live
viru
associ
express
nonstructur
fmdv
protein
indic
viru
replic
cycl
initi
format
doubl
strand
rna
potenti
trigger
respons
although
known
main
sensor
rna
virus
pdc
repres
receptor
singl
strand
rna
therefor
interest
determin
role
play
sens
fmdv
fmdv
immun
complex
end
use
immunoregulatori
sequenc
repres
odn
inhibitor
previous
establish
human
murin
immun
system
employ
influenza
virusstimul
pdc
known
ligand
test
effici
inhibit
pathway
porcin
pdc
shown
figur
complex
employ
inhibit
pdc
respons
figur
similar
level
inhibit
also
observ
fmdv
isol
data
shown
control
odn
influenc
product
fmdvstimul
pdc
data
shown
pdc
cultur
permit
detect
effici
opsonis
fmdv
absenc
neutral
next
interest
determin
whether
opsonis
activ
also
detect
absenc
neutral
activ
end
antio
manisa
serum
employ
test
fmdv
ukg
nt
log
brazil
nt
detect
limit
interestingli
despit
inabl
neutral
serotyp
viru
opsonis
activ
virus
observ
similar
serum
dilut
log
also
maximum
product
reach
serum
dilut
log
fmdv
isol
figur
experi
repeat
five
differ
batch
pdc
prepar
enhanc
respons
immun
serum
compar
effect
naiv
serum
consist
observ
despit
variabl
height
respons
figur
similar
result
also
obtain
anoth
serum
sampl
obtain
second
vaccin
pig
data
shown
furthermor
sera
also
abl
opson
confirm
exist
opson
antibodi
crossreact
serotyp
consid
surpris
result
neutral
opsonis
activ
antio
manisa
serum
measur
collect
fmdv
isol
serotyp
c
result
summar
tabl
nt
opsonis
titr
ot
repres
highest
serum
dilut
abl
opsonis
fmdv
enhanc
respons
expect
immun
serum
abl
neutral
serotyp
virus
ukg
vietnam
virus
found
similar
ot
log
respect
shown
figur
nonneutr
brazil
could
opsonis
titr
log
also
fmdv
turkey
albeit
lesser
extent
opsonis
although
neutral
neither
neutral
opsonis
antio
manisa
serum
result
demonstr
opsonis
fmdv
occur
absenc
neutral
pdc
profession
sensor
virus
produc
larg
amount
typei
ifn
howev
particular
nonenvelop
virus
fmdv
shown
unabl
trigger
pdc
activ
vitro
unless
cell
stimul
immun
complex
viru
howev
present
studi
demonstr
fmdv
activ
pdc
also
absenc
specif
antibodi
improv
purif
method
employ
typec
opson
titr
repres
minimum
serum
dilut
abl
enhanc
respons
pdc
calcul
independ
experi
describ
figur
also
demonstr
immunecomplex
fmdv
uncomplex
fmdv
activ
pdc
via
expect
respons
pdc
fmdv
possibl
pure
popul
pdc
result
also
indic
factor
could
import
percentag
cell
type
present
cell
cultur
observ
vivo
respons
occur
earli
innat
phase
immun
respons
cattl
pig
support
idea
earli
activ
pdc
fmdv
absenc
specif
antibodi
support
vivo
relev
data
fact
cattl
demonstr
pdc
sourc
earli
respons
studi
also
demonstr
remark
differ
differ
fmdv
isol
activ
pdc
reason
differ
activ
pdc
could
either
relat
uptak
viru
pdc
function
viral
gene
ifn
antagonist
l
pro
viral
proteinas
fmdv
interact
immun
nonimmun
cell
via
argglyasp
rgd
depend
rgdindepend
mechan
cell
cultur
adapt
heparin
sulphat
bind
certainli
differ
observ
pdc
relat
cell
cultur
adapt
certain
fmdv
isol
heparin
sulphat
bind
sinc
virus
employ
studi
maximum
three
passag
furthermor
compar
cell
cultur
adapt
heparinsulph
bind
viru
nonadapt
origin
wildtyp
fmdv
virus
describ
found
differ
abil
activ
pdc
data
shown
hand
leader
proteinas
l
pro
inhibit
typei
ifn
pathway
variabl
among
serotyp
could
contribut
isolatespecif
fmdv
counteract
induct
pdc
potenti
fmdv
isol
consist
induc
also
low
moi
would
support
hypothesi
overal
import
note
comparison
level
respons
influenza
virus
cpg
fmdv
poor
stimul
pdc
nevertheless
consid
known
effici
inhibit
fmdv
replic
vitro
vivo
import
investig
relationship
abil
fmdv
isol
induc
vitro
promot
vivo
innat
adapt
immun
respons
previou
studi
demonstr
antibodydepend
intern
fmdv
via
repres
import
pathway
enter
macrophag
pdc
one
main
object
studi
determin
relationship
opsonis
neutral
nonneutr
serotypea
isol
could
effici
opsonis
use
antio
serum
other
serotyp
c
isol
phylogenet
studi
base
amino
acid
sequenc
contain
antigen
site
serotyp
belong
branch
serotyp
c
distant
partial
explain
find
interestingli
opsonis
effici
occur
serum
dilut
similar
requir
neutral
antigen
relat
virus
serotyp
employ
would
indic
type
antibodi
specif
similar
function
howev
also
found
opsonis
nonneutr
condit
contradict
idea
could
specul
opsonis
activ
possibl
lower
avid
compar
neutral
antibodi
bind
viru
competit
viru
bind
cellular
receptor
competit
occur
indirectli
opsonis
sinc
cellular
fcr
bind
fc
portion
antibodi
observ
opsonis
occur
similar
serum
dilut
neutral
nonneutr
viru
would
favour
presenc
nonneutr
epitop
conserv
differ
serotyp
answer
question
need
address
use
monoclon
antibodi
rather
polyclon
serum
current
studi
broad
activ
opsonis
antibodi
interest
frame
vaccineinduc
immun
respons
nonneutr
vaccineinduc
antibodi
could
enhanc
innat
immun
respons
antigen
less
relat
fmdv
challeng
strain
restrict
abil
replic
furthermor
fcrmediat
function
viru
phagocytosi
effici
antigen
present
viral
antigen
cell
could
promot
although
suffici
mediat
complet
protect
diseas
could
limit
viru
replic
sever
clinic
diseas
transmiss
within
heard
futur
studi
requir
determin
respons
correl
protect
partial
complet
case
vaccin
improv
promot
broadli
reactiv
antibodi
respons
abl
link
innat
adapt
immun
fmdv
via
opsonis
antibodi
